A. Fathi, B. D. Smith, A. Angiolillo, G. Binder, J. Hui, Rachel Guo, C. Cerchione
{"title":"与安慰剂(PBO) + AZA相比,Ivosidenib (IVO) + Azacitidine (AZA)治疗新诊断急性髓系白血病(AML)患者的骨髓抑制消退时间和相关住院治疗","authors":"A. Fathi, B. D. Smith, A. Angiolillo, G. Binder, J. Hui, Rachel Guo, C. Cerchione","doi":"10.1016/s2152-2650(23)01062-5","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":10370,"journal":{"name":"Clinical Lymphoma Myeloma and Leukemia","volume":"31 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"AML-446 Time to Resolution of Myelosuppression and Associated Hospitalization in Patients With Newly-Diagnosed Acute Myeloid Leukemia (AML) Treated With Ivosidenib (IVO) + Azacitidine (AZA) Compared to Placebo (PBO) + AZA\",\"authors\":\"A. Fathi, B. D. Smith, A. Angiolillo, G. Binder, J. Hui, Rachel Guo, C. Cerchione\",\"doi\":\"10.1016/s2152-2650(23)01062-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":10370,\"journal\":{\"name\":\"Clinical Lymphoma Myeloma and Leukemia\",\"volume\":\"31 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lymphoma Myeloma and Leukemia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s2152-2650(23)01062-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma Myeloma and Leukemia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s2152-2650(23)01062-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
AML-446 Time to Resolution of Myelosuppression and Associated Hospitalization in Patients With Newly-Diagnosed Acute Myeloid Leukemia (AML) Treated With Ivosidenib (IVO) + Azacitidine (AZA) Compared to Placebo (PBO) + AZA